Interestingly, compared with CTCs in metastatic patients, the DTCs in the bone marrow of early HER2-positive breast cancer patients presented increased expression of stem cell markers such as ALDH1, CAV1 and VIM [42]. This evidence concerns the gene ERBB2 and breast carcinoma.